Loading

Investor Relations

Corporate Profile

We are a late stage biopharmaceutical company focused on the development and commercialization of serlopitant for the treatment of pruritus, or itch, associated with various conditions. We believe that serlopitant, a highly selective small molecule inhibitor of the neurokinin 1 receptor, or NK1R, given as a once daily, oral tablet, has the potential to significantly alleviate pruritus associated with various conditions.

Copyright West LLC. Minimum 15 minutes delayed.

Events

Menlo Therapeutics Presents Successful Phase 2 Clinical Trial Results of Serlopitant in Psoriasis at the European Academy of Dermatology and Venereology Meeting

REDWOOD CITY, Calif. , Oct. 11, 2019 (GLOBE NEWSWIRE) -- Menlo Therapeutics Inc. (Nasdaq: MNLO), a late-stage biopharmaceutical company, presented results from its successful Phase 2 clinical trial of serlopitant for the treatment of pruritis in patients with psoriasis in an oral presentation at

Menlo Therapeutics to Present at the 2019 Cantor Global Healthcare Conference

REDWOOD CITY, Calif. , Sept. 26, 2019 (GLOBE NEWSWIRE) -- Menlo Therapeutics Inc. (NASDAQ: MNLO), a late-stage biopharmaceutical company focused on the development of serlopitant for the treatment of pruritus (itch), today announced that Steven Basta , chief executive officer of Menlo Therapeutics

Menlo Therapeutics Announces Completion of Enrollment of 233 Patients in Phase 2 Trial of Serlopitant in Patients with Chronic Pruritus of Unknown Origin

- Results expected in Q1 2020 - REDWOOD CITY, Calif. , Sept. 24, 2019 (GLOBE NEWSWIRE) -- Menlo Therapeutics Inc. (Nasdaq: MNLO), a late-stage biopharmaceutical company, today announced that it has completed patient enrollment in its Phase 2 clinical trial evaluating the safety and efficacy of once